CriticalAntiepileptics. Carboxamide derivatives×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
The liver clears voriconazole through the enzymes CYP2C19, CYP2C9 and CYP3A4, and drugs that speed up these enzymes lower its blood levels (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Carbamazepine strongly induces CYP3A4 and other liver enzymes (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), including CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 (carbamazepine label, US Food and Drug Administration, FDA). No study has tested the combination. According to the voriconazole SmPC and label, carbamazepine is likely to lower voriconazole levels markedly, and the antifungal effect may be lost (voriconazole SmPC, EMA, and label, FDA). In the other direction, voriconazole inhibits CYP3A4, the main route of carbamazepine metabolism in the liver. The carbamazepine documents list voriconazole among the azoles that raise carbamazepine blood levels (carbamazepine SmPC, AEMPS, and label, FDA).
Symptoms
The drop in voriconazole levels itself causes no symptoms: the only sign is that the fungal infection does not improve or comes back on the usual dose. Voriconazole treats invasive aspergillosis, candidaemia and other serious fungal infections, mainly when the infection is progressing and may be life-threatening. It also prevents fungal infections after haematopoietic stem cell transplant, so loss of its effect is dangerous (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Too much carbamazepine causes dizziness, drowsiness, loss of coordination (ataxia) and double vision (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Severe carbamazepine overdose can cause reduced consciousness or even coma, seizures, respiratory depression, tachycardia, low blood pressure, cardiac conduction disorders with QRS widening and low blood sodium (carbamazepine SmPC, AEMPS).
Management
The combination is contraindicated. Voriconazole must not be given with carbamazepine, because carbamazepine induces liver enzymes and markedly lowers voriconazole levels (voriconazole summaries of product characteristics, SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS; voriconazole label, US Food and Drug Administration, FDA). According to the Spanish carbamazepine SmPC, a patient treated with voriconazole may need a different anticonvulsant (carbamazepine SmPC, AEMPS). In epilepsy, do not stop carbamazepine abruptly, because sudden withdrawal can trigger seizures. If it has to be stopped at once, switch to another antiepileptic under cover of a suitable drug, for example intravenous or rectal diazepam (carbamazepine SmPC, AEMPS). The same SmPC also lists intravenous phenytoin as cover, but voriconazole should not be combined with phenytoin unless the benefit outweighs the risk. Long-acting barbiturates such as phenobarbital are contraindicated with voriconazole (voriconazole SmPC, EMA). The documents give no waiting time between stopping carbamazepine and starting voriconazole. If the two drugs have nevertheless been taken together, monitor carbamazepine blood levels and adjust the dose if needed, because azoles, including voriconazole, raise them. The usual total level in epilepsy is about 4–12 micrograms/mL (carbamazepine SmPC, AEMPS, and label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- AEMPS: Ficha técnica: Carbamazepina (nº registro 62621), sección 4.5 (2025)– AEMPS, CIMA, nº registro 62621, sección 4.5
- AEMPS: Ficha técnica: Voriconazol (nº registro 80105), sección 4.3 (2026)– AEMPS, CIMA, nº registro 80105, revisión 04/2026, sección 4.3
- AEMPS: Ficha técnica: Carbamazepina, Tegretol 200 mg (nº registro 39955), sección 4.5 (2026)– AEMPS, CIMA, nº registro 39955, revisión 09/2026, secciones 4.3 y 4.5
- FDA: Tegretol (carbamazepine) prescribing information (2026)– FDA label, DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053, version 39, revised 08/2026, Contraindications and PRECAUTIONS: Drug Interactions
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5